WELLESLEY, MA – November 1st, 2018, Censa Pharmaceuticals Inc., a biopharmaceutical company focused on the development of CNSA-001 for orphan diseases, announced that it has successfully completed a Phase I study and has initiated enrollment into several Phase II studies. The Phase I study showed CNSA-001’s favorable safety profile and promising pharmacokinetic & pharmacodynamic characteristics. The Company is now looking to demonstrate CNSA-001’s efficacy in diseases known to be associated with suboptimal tetrahydrobiopterin related pathways. “The completion of our Phase I study and the initiation of phase II studies represent the culmination of extensive efforts over the last two years from our employees, investigators, clinical trial sites, contract research organization, caregivers and patients. Given the safety profile to date, excellent pharmacological properties of CNSA-001 and available pre-clinical and clinical data, CNSA-001 is well-positioned to demonstrate a clinical effect in our key target indications. Censa is looking forward to working with the FDA on the shortest regulatory path to approval so that CNSA-001 becomes available to patients with devastating diseases” said Neil Smith PharmD, MBA, Head of R&D and VP Operations.
About Censa Pharmaceuticals
Censa Pharmaceuticals Inc., headquartered in Wellesley, MA, is developing CNSA-001 to improve the lives of patients with debilitating diseases. CNSA-001 which contains sepiapterin, a precursor of tetrahydrobiopterin, targets orphan metabolic and central nervous system diseases. For more information, visit www.censapharma.com